- Home
- CODA vs PLRX Comparison
CODA vs PLRX Comparison
Compare CODA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | PLRX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CODA | PLRX |
|---|---|---|
| Price | $9.04 | $1.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $3.79 |
| AVG Volume (30 Days) | 44.2K | ★ 1.8M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $24,347,217.00 | N/A |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $20.84 | N/A |
| P/E Ratio | $30.17 | ★ N/A |
| Revenue Growth | ★ 29.34 | N/A |
| 52 Week Low | $5.76 | $1.10 |
| 52 Week High | $10.54 | $15.00 |
Technical Indicators
Market Signals| Indicator | CODA | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 34.01 |
| Support Level | $8.34 | $1.17 |
| Resistance Level | $9.00 | $1.35 |
| Average True Range (ATR) | 0.39 | 0.12 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 94.44 | 15.38 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.